|
1
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al: Global surveillance cancer survival 1995–2009: Analysis of
individual data for 25,676,887 patients from 279 population-based
registries in 67 countries (CONCORD-2). Lancet. 385:977–1010. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Sosiety, . Cancer Facts
and Figures 2017. Atlanta, Ga: American Cancer Society; 2017
|
|
3
|
Pfisterer J and Ledermann JA: Management
of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 33 2
Suppl 6:S12–S16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakayama K, Nakayama N and Miyazaki K:
Development of a novel ovarian cancer molecular target therapy
against cancer related transcriptional factor, NAC1. J Obstet
Gynaecol Res. 39:18–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agarwal R, Linch M and Kaye SB: Novel
therapeutic agents in ovarian cancer. Eur J Surg Oncol (EJSO).
32:875–886. 2006. View Article : Google Scholar
|
|
6
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimizu S, Kanaseki T, Mizushima N, Mizuta
T, Arakawa-Kobayashi S, Thompson CB and Tsujimoto Y: Role of Bcl-2
family proteins in a non-apoptotic programmed cell death dependent
on autophagy genes. Nat Cell Biol. 6:1221–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rashmi R, Pillai SG, Vijayalingam S,
Ryerse J and Chinnadurai G: BH3-only protein BIK induces
caspase-independent cell death with autophagic features in Bcl-2
null cells. Oncogene. 27:1366–1375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furuya D, Tsuji N, Yagihashi A and
Watanabe N: Beclin 1 augmented cis-diamminedichloroplatinum induced
apoptosis via enhancing caspase-9 activity. Exp Cell Res.
307:26–40. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun Y, Liu JH, Jin L, Pan L, Sui YX, Yang
Y and Shi H: Beclin 1 influences cisplatin-induced apoptosis in
cervical cancer CaSki cells by mitochondrial dependent pathway. Int
J Gynecol Cancer. 22:1118–1124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J: Beclin 1 bridges autophagy,
apoptosis and differentiation. Autophagy. 4:947–948. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eskelinen EL and Saftig P: Autophagy: A
lysosomal degradation pathway with a central role in health and
disease. Biochim Biophys Acta. 1793:664–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mizushima N: Methods for monitoring
autophagy. Int J Biochem Cell Biol. 36:2491–2502. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang D, Kang R, Cheh CW, Livesey KM, Liang
X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, et
al: HMGB1 release and redox regulates autophagy and apoptosis in
cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai M, Hu Z, Liu J, Gao J, Liu C, Liu D,
Tan M, Zhang D and Lin B: Beclin 1 expressin in ovarian tissues and
its effect on ovarian cancer prognosis. Int Mol Sci. 15:5292–5303.
2014. View Article : Google Scholar
|
|
16
|
Odicino F, Pecorelli S, Zigliaani L and
Creasman WT: History of the FIGO cancer staging system. Int J
Gyneacol Obstet. 101:205–210. 2008. View Article : Google Scholar
|
|
17
|
Katagiri H, Nakayama K, Razia S, Nakamura
K, Sato E, Ishibashi T, Ishikawa M, Iida K, Ishikawa N, Otsuki Y,
et al: Loss of autophagy-related protein Beclin 1 may define poor
prognosis in ovarian clear cell carcinomas. Int J Oncol.
47:2037–2044. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:1–288. 2012.PubMed/NCBI
|
|
19
|
Nakayama K, Rahman MT, Rahman M, Yeasmin
S, Ishikawa M, Katagiri A, Iida K, Nakayama N and Miyazaki K:
Biological role and prognostic significance of NAC1 in ovarian
cancer. Gynecol Oncol. 119:469–478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Díaz-Montes TP and Bristow RE: Secondary
cytoreduction for patients with recurrent ovarian cancer. Curr
Oncol Rep. 7:451–458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harter P and du Bois A: The role of
surgery in ovarian cancer with special emphasis on cytoreductive
surgery for recurrence. Curr Opin Oncol. 17:505–514. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gadducci A, Iacconi P, Cosio S, Fanucchi
A, Cristofani R and Riccardo Genazzani A: Complete salvage surgical
cytoreduction improves further survival of patients with late
recurrent ovarian cancer. Gynecol Oncol. 79:344–349. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gadducci A, Iacconi P, Fanucchi A, Cosio
S, Teti G and Genazzani AR: Surgical cytoreduction during
second-look laparotomy in patients with advanced ovarian cancer.
Anticancer Res. 20:1959–1964. 2000.PubMed/NCBI
|
|
24
|
Zang RY, Li ZT, Tang J, Cheng X, Cai SM,
Zhang ZY and Teng NN: Secondary cytoreductive surgery for patients
with relapsed epithelial ovarian carcinoma: Who benefits? Cancer.
100:1152–1161. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin HX, Qiu HJ, Zeng F, Rao HL, Yang GF,
Kung HF, Zhu XF, Zeng YX, Cai MY and Xie D: Decreased expression of
Beclin 1 correlates closely with Bcl-xL expression and poor
prognosis of ovarian carcinoma. PLoS One. 8:e605162013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng
ZY, Ding YG, Wan XB, Guan Z, Li HG, et al: Low expression of Beclin
1, associated with high Bcl-xL, predicts a malignant phenotype and
poor prognosis of gastric cancer. Autophagy. 8:389–400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu DM, Wang GL, Chen L, Xu YY, He S, Cao
XL, Qin J, Zhou JM, Zhang YX and E Q: The expression of beclin-1,
an autophagic gene, in hepatocellular carcinoma associated with
clinical pathological and prognostic significance. BMC Cancer.
14:3272014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Giatromanolaki A, Koukourakis MI,
Koutsopoulos A, Chloropoulou P, Liberis V and Sivridis E: High
Beclin 1 expression defines a poor prognosis in endometrial
adenocarcinomas. Gynecol Oncol. 123:147–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nishikawa M, Miyake H, Liu B and Fujisawa
M: Expression pattern of autophagy-related markers in
non-metastatic clear cell renal cell carcinoma: Association with
disease recurrence following radical nephrectomy. J Cancer Res Clin
Oncol. 141:1585–1591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han Y, Xue XF, Shen HG, Guo XB, Wang X,
Yuan B, Guo XP, Kuang YT, Zhi QM and Zhao H: Prognostic
significance of Beclin-1 expression in colorectal cancer: A
meta-analysis. Asian Pac J Cancer Prev. 15:4583–4587. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rohatgi RA, Janusis J, Leonard D, Bellvé
KD, Fogarty KE, Baehrecke EH, Corvera S and Shaw LM: Beclin 1
regulates growth factor receptor signaling in breast cancer.
Oncogene. 34:5352–5362. 2015. View Article : Google Scholar : PubMed/NCBI
|
